Recruiting
Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
An observational study of patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage, employing multimodal neuromonitoring.
ClinicalTrials.gov IDNCT07305922
PhaseNot Applicable
Enrollment200
SponsorRegion Stockholm
Age18 Years and older
SexALL
Conditions studied
Subarachnoid Aneurysm Hemorrhage, Cerebral Vasospasm After Subarachnoid Hemorrhage
About this study
An observational study of patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage, employing multimodal neuromonitoring.
Interventions
- Drug: Induced hypertension with norepinephrine — Induced hypertension with norepinephrine and/or dobutamine to attain clinically established goals of cerebral perfusion pressure in a stepwise fashion, according to clinical routine.
- Drug: Endoluminal Spasmolysis — Endoluminal spasmolysis of cerebral arteries using i.a. Nimodipine, according to clinical protocol and neurointerventionist discretion.
Primary outcomes
- Mean Flow Velocity (MFV) (Up to 12 hours post intervention)
Eligibility information
Inclusion Criteria:
* Adults 18 years or older
* Critical care after subarachnoid haemorrhage
* Aneurysm secured by surgical clipping or endovascular procedure
* Suspected, emerging or established severe cerebral vasospasm
Exclusion Criteria:
* Anticipated survival less than five days, as determined by treating clinician
* Transcranial Doppler signal too weak
* Pregnancy
Study locations
- Karolinska University Hospital, Stockholm, 17176 Sweden
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-12.